Literature DB >> 12530467

Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A.

Akiko Soyama1, Nobumitsu Hanioka, Yoshiro Saito, Norie Murayama, Masanori Ando, Shogo Ozawa, Jun-ichi Sawada.   

Abstract

Amiodarone is a potent Class III antiarrhythmic drug. The N-deethylation of amiodarone to desethylamiodarone is known to be catalyzed by cytochrome P450 (CYP) 2C8. In the present study, amiodarone N-deethylation by the CYP2C8s, CYP2C8*1 (wild-type), CYP2C8*3, and CYP2C8 P404A (Pro404Ala substitution in exon 8), was investigated by their transient expression in Hep G2 cells. The expression levels of CYP2C8*1 and CYP2C8*3 were similar, whereas the level of CYP2C8 P404A was 55.6% of that of CYP2C8*1. The kinetic parameters of amiodarone N-deethylation were obtained by means of Lineweaver-Burk analysis. The intrinsic clearance (Vmax/Km, per mg of microsomal protein) of amiodarone by CYP2C8 P404A but not CYP2C8*3 was significantly (48.7%) less than that of CYP2C8*1. These results suggest that CYP2C8 P404A but not CYP2C8*3 is less effective in the N-deethylation of amiodarone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530467     DOI: 10.1034/j.1600-0773.2002.910404.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  20 in total

1.  The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.

Authors:  Tanja Busk Bidstrup; Per Damkier; Anette Kristensen Olsen; Marianne Ekblom; Anders Karlsson; Kim Brøsen
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

2.  Genetic polymorphisms of CYP2C8 in the Czech Republic.

Authors:  Kristina Pechandova; Helena Buzkova; Olga Matouskova; Frantisek Perlik; Ondrej Slanar
Journal:  Genet Test Mol Biomarkers       Date:  2012-02-07

Review 3.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

Authors:  Rüdiger Kaspera; Suresh B Naraharisetti; Eric A Evangelista; Kristin D Marciante; Bruce M Psaty; Rheem A Totah
Journal:  Biochem Pharmacol       Date:  2011-06-24       Impact factor: 5.858

Review 5.  Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors:  Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 6.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

7.  Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.

Authors:  Rüdiger Kaspera; Suresh B Naraharisetti; Bani Tamraz; Tariku Sahele; Matthew J Cheesman; Pui-Yan Kwok; Kristin Marciante; Susan R Heckbert; Bruce M Psaty; Rheem A Totah
Journal:  Pharmacogenet Genomics       Date:  2010-10       Impact factor: 2.089

Review 8.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

9.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Authors:  Elizabeth B Daily; Christina L Aquilante
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

Review 10.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Authors:  Christina L Aquilante; Mikko Niemi; Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.